STOCK TITAN
  1. Home
  2. News
  3. INMD

InMode Ltd. Ordinary Shares - INMD STOCK NEWS

Welcome to our dedicated page for InMode Ltd. Ordinary Shares news (Ticker: INMD), a resource for investors and traders seeking the latest updates and insights on InMode Ltd. Ordinary Shares stock.

InMode Ltd. (NASDAQ: INMD) is a leading global provider of innovative medical technologies specializing in minimally and non-invasive surgical aesthetic and medical treatment solutions. The company's product portfolio spans three major energy-based treatment categories: face & body contouring, medical aesthetics, and women's health. Their products, such as BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF, and Morpheus8, are widely utilized in plastic surgery, dermatology, gynecology, and ophthalmology.

InMode’s flagship products, including Fractora for skin texture improvement, Lumecca for photorejuvenation, Diolaze for hair removal, and BodyFX for body contouring, are designed to deliver effective and exciting aesthetic solutions.

InMode has consistently invested in research and development to expand its intellectual property portfolio, which is pivotal for maintaining its competitive edge. Recently, the company initiated legal action against BTL Industries for patent infringement regarding their radio-frequency based feminine rejuvenation products.

Despite market headwinds, including higher interest rates affecting equipment financing and slower purchase decisions, InMode has shown resilience with a 2% increase in Q3 2023 revenues, totaling $123.1 million. The company also saw a 13% rise in international sales during this period.

In Q1 2024, InMode announced pre-orders for two new platforms, IgniteRF and Optimus Max, which are anticipated to drive future growth. Additionally, a new share repurchase program and the appointment of Dr. Michael Anghel as Chairman of the Board underscore the company’s commitment to shareholder value.

InMode's innovative spirit is further highlighted by their recent partnership with P1 Offshore Racing, sponsoring the only female driver, Victoria Rand, signaling a strong commitment to empowering women.

For more detailed information and the latest updates, visit InMode's official website.

News

InMode Reports Fourth Quarter and Full Year 2023 Financial Results; Quarterly Revenue of $126.8M and Record Full Year Revenue of $492M

Rhea-AI Summary
InMode Ltd. (INMD) reports strong financial results for Q4 2023 and FY 2023 with record revenues, net income, and international growth. Quarterly revenue was $126.8 million, with a 20% increase in consumables and service revenue. Full-year revenue reached $492 million, with GAAP net income of $197.9 million and non-GAAP net income of $221.5 million. International revenues saw an 18% increase. The company's cash position stood at $741.6 million as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.65%
Tags
earnings
-
News

InMode to Report Fourth Quarter & Full Year 2023 Financial Results and Hold Conference Call on Feb. 13, 2024, Expects Q4 Revenue Between $126.0M-$126.5M

Rhea-AI Summary
InMode Ltd. (INMD) is set to release its financial results for the fourth quarter and full year 2023 on February 13, 2024. The company expects revenue for the fourth quarter to be between $126.0 million and $126.5 million, with full-year revenue in the range of $491.3 million to $491.8 million. Non-GAAP earnings per diluted share for the same periods are expected to be between $0.68 and $0.69, and $2.54 to $2.55, respectively. The company anticipates a non-GAAP gross margin for the full year of 2023 to be in the range of 83% to 85%. Additionally, InMode projects revenue for the full year 2024 to be between $495 million and $505 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.8%
Tags
conferences earnings
-
News

InMode Revises Full-Year 2023 Guidance

Rhea-AI Summary
InMode Ltd. (INMD) revises its full-year 2023 guidance due to stronger-than-expected headwinds from the current macroeconomic environment, resulting in a slowdown in platform sales, mainly in North America. Revenue for the full year 2023 is expected to be in the range of $485-495 million, with non-GAAP gross margin remaining at 83-85% and non-GAAP income from operations in the range of $214-218 million. Non-GAAP earnings per diluted share for the full year 2023 are expected to be in the range of $2.47-2.50.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.99%
Tags
none
News

InMode to Present at Upcoming Investor Conferences and Events

Rhea-AI Summary
InMode Ltd. (NASDAQ: INMD) will be participating in several investor conferences and events in November and December. The company will be presenting at the Jefferies London Healthcare Conference on Nov. 14 and participating in one-on-one meetings. In addition, InMode will be attending the Canaccord MTDF Investor Conference on Nov. 16 and the Mizuho Medical Device and Healthcare Services Summit on Dec. 6, both in New York.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.7%
Tags
conferences
-
News

InMode Reports Third Quarter 2023 Financial Results; Quarterly Revenue of $123.1M Represents 2% Year-Over-Year Growth

Rhea-AI Summary
InMode Ltd. (Nasdaq: INMD) announced its Q3 2023 financial results. The company reported quarterly revenue of $123.1 million, a 2% increase compared to Q3 2022. InMode's proprietary surgical technology platforms accounted for 83% of revenues, followed by hands-free platforms at 9% and traditional laser and non-invasive RF platforms at 8%. The company's GAAP net income was $46.5 million, while non-GAAP net income was $53.1 million. Quarterly revenues from consumables and service reached $17.9 million, a 28% increase from Q3 2022. InMode's total cash position as of September 30, 2023, was $675.8 million, including cash, cash equivalents, marketable securities, and short-term bank deposits.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.35%
Tags
earnings
-
News

InMode Files Patent Infringement Complaint Against BTL Industries, Inc. (d/b/a BTL Aesthetics)

Rhea-AI Summary
InMode files patent infringement complaint against BTL Industries
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.37%
Tags
none
News

InMode Expects Third Quarter 2023 Revenue Between $122.8M-$123.0M, Lowering Full-Year 2023 Revenue Guidance to $500M-$510M vs. Original Estimates of $530M-$540M

Rhea-AI Summary
InMode Ltd. expects to release its financial results for Q3 2023 on Nov. 2, 2023. Preliminary results suggest a downtick in platform sales due to economic slowdown and financing constraints. Revenue for Q3 2023 is expected to be in the range of $122.8 million to $123.0 million. Non-GAAP earnings per diluted share for Q3 2023 are expected to be in the range of $0.59 to $0.60. Revenue for the full year of 2023 is expected to be in the range of $500 million to $510 million. Non-GAAP gross margin for Q3 2023 is expected to be in the range of 83% to 85%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.97%
Tags
earnings
-
News

InMode Affirms Safety of Management, Employees and Production Sites

Rhea-AI Summary
InMode Ltd. addresses the status of its activity in Israel, assuring no interruption to production and prioritizing employee safety. Inventory levels are sufficient for the next three quarters. Revenues generated from Israel account for less than 1%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.31%
Tags
none
-
News

InMode to Present at Upcoming Investor Conferences and Events

Rhea-AI Summary
InMode Ltd. announces participation in investor conferences and events in September.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.47%
Tags
conferences
News

InMode to Present at Upcoming Investor Conferences and Events

Rhea-AI Summary
InMode Ltd. to participate in investor conferences and events in August.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.17%
Tags
conferences

FAQ

What is the current stock price of InMode Ltd. Ordinary Shares (INMD)?

The current stock price of InMode Ltd. Ordinary Shares (INMD) is $17.08 as of December 20, 2024.

What is the market cap of InMode Ltd. Ordinary Shares (INMD)?

The market cap of InMode Ltd. Ordinary Shares (INMD) is approximately 1.3B.

What products does InMode Ltd. offer?

InMode offers a range of innovative aesthetic solutions including BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF, and Morpheus8.

What are InMode's core business categories?

InMode's core business categories include face & body contouring, medical aesthetics, and women's health.

Which markets does InMode serve?

InMode serves markets including plastic surgery, dermatology, gynecology, and ophthalmology.

How did InMode perform in Q3 2023?

In Q3 2023, InMode reported revenues of $123.1 million, a 2% increase from the same period in 2022, and a 13% increase in international sales.

What are some of InMode's flagship products?

InMode's flagship products include Fractora, Lumecca, Diolaze, and BodyFX, offering solutions for skin texture improvement, photorejuvenation, hair removal, and body contouring.

What recent legal actions has InMode taken?

InMode filed a patent infringement complaint against BTL Industries concerning their radio-frequency based feminine rejuvenation products.

What new platforms has InMode recently announced?

InMode has announced pre-orders for two new platforms, IgniteRF and Optimus Max, expected to drive future growth.

Who is the new Chairman of InMode's Board?

Dr. Michael Anghel has been appointed as the new Chairman of InMode's Board, effective July 25, 2024.

What partnership has InMode recently entered into?

InMode partnered with P1 Offshore Racing and is sponsoring the only female driver, Victoria Rand, as part of Class 1.

Where can I find more information about InMode?

For more information and the latest updates, visit InMode's official website at https://inmodemd.com/.

Stock INMD logo
InMode Ltd. Ordinary Shares

Nasdaq:INMD

INMD Rankings

#2316 Ranked by Market Cap
N/A Ranked by Dividends

INMD Stock Data

1.30B
68.05M
10.76%
64.22%
8.44%
Medical Devices
Healthcare
Link
United States of America
Yokne'am